Evidence map›Paper›PMID 40430352›Full record

ArticleMolecules (Basel, Switzerland)2025

Docking-Based Classification of SGLT2 Inhibitors.

Ajouan Mazoudji, Gerhard F Ecker

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ajouan MazoudjiDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2 (UZA II), 1090 Vienna, Austria.ORCID 0009-0003-7986-5495
Gerhard F EckerDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2 (UZA II), 1090 Vienna, Austria.ORCID 0000-0003-4209-6883

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitors of the Sodium/Glucose co-transporter 2 (SGLT2) have been evolving into an important contribution to the treatment of diabetes mellitus. As the inhibition of SGLT2 is sensitive to the structural configuration at the sugar moiety of the inhibitors, it is of high interest to provide in silico-based methods for the prediction of the activity of potential SGLT2 inhibitors that take three-dimensional information into account. To attain this objective, a classification model based on the docking scores obtained from the best-performing docking-based virtual screening was created. Furthermore, the impact of ensemble docking using docking results from five SGLT2 structures and the incorporation of structural similarity information was assessed by creating classification models using these approaches. Taking a combined approach of docking score and structural similarity modelling led to the best performance with a Matthews Correlation Coefficient (MCC) of 0.64. Finally, to explore the ability of the used docking algorithms to correctly predict the influence of different three-dimensional information, a library of molecules with a negatively contributing configuration was created and docked, showing decreased docking scores for the molecule library with a disadvantaged configuration.

Indexed as

Molecular Docking SimulationSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsAlgorithmsHumansProtein BindingSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsclassification modelsdiabetesdockingSGLT2SLC5A2

Identifiers

PMID40430352
PMCPMC12114233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.